Accelerating Toward Human Trials
Carnosic acid is currently deemed as “safe” by the FDA, therefore researchers state it should be fast-tracked to clinical trials so Alzheimer’s patients can receive treatment as soon as possible. Researchers emphasize that diAcCA’s safety profile and oral administration route simplify dosing compared to intravenous therapies. With carnosic acids’ limited potential for adverse side effects, researchers believe diAcCA will possibly save lives without creating serious negative effects, increasing its efficacy tenfold. This is because carnosic acid only activates and affects in parts of the brain that are inflamed.
If human trials show the same results as the mouse trials, this rosemary compound for Alzheimer’s could become one of the first treatments to reverse, rather than merely slowing down, cognitive degenerative diseases and their effects. Beyond Alzheimer’s, the anti-inflammatory properties of diAcCA may benefit other conditions, including Parkinson’s disease, type 2 diabetes, and heart disease. Dr. Lipton’s team plans to explore these applications, leveraging the compound’s versatile applications.